Image may be NSFW.
Clik here to view.
Parvus Therapeutics said today that it signed an exclusive worldwide license and collaboration deal with Novartis (NYSE:NVS) for its type 1 diabetes nanodrug, Navacim. The therapeutic candidate is made up of iron oxide nanoparticles coated with a peptide derived from a pancreatic autoantigen, according to Parvus.
Navacims are the 1st biopharmaceuticals to restore immune tolerance through the formation of regulatory T-cells in prelinical models without suppressing the immune system, the company reported.
Get the full story at our sister site, Drug Delivery Business News.
The post Parvus inks exclusive license with Novartis for T1D nanomedicine appeared first on MassDevice.
